Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

Alan J. Thompson; William Carroll; Olga Ciccarelli; Giancarlo Comi; Anne Cross; Alexis Donnelly; Anthony Feinstein; Robert J. Fox; Anne Helme; Reinhard Hohlfeld; Robert Hyde; Pamela Kanellis; Douglas Landsman; Catherine Lubetzki; Ruth Ann Marrie; Julia Morahan; Xavier Montalban; Bruno Musch; Sarah Rawlings; Marco Salvetti; Finn Sellebjerg; Caroline Sincock; Kathryn E. Smith; Jon Strum; Paola Zaratin; Timothy Coetzee

doi:10.1177/13524585211059766

Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

Alan J. Thompson, William Carroll, Olga Ciccarelli, Giancarlo Comi, Anne Cross, Alexis Donnelly, Anthony Feinstein, Robert J. Fox, Anne Helme, Reinhard Hohlfeld, Robert Hyde, Pamela Kanellis, Douglas Landsman, Catherine Lubetzki, Ruth Ann Marrie, Julia Morahan, Xavier Montalban, Bruno Musch, Sarah Rawlings, Marco SalvettiFinn Sellebjerg, Caroline Sincock, Kathryn E. Smith, Jon Strum, Paola Zaratin, Timothy Coetzee^*

^*Autor corresponent d’aquest treball

Departament de Medicina

Producció científica: Contribució a revista › Article de revisió › Recerca › Avaluat per experts

15 Cites (Scopus)

Resum

Background: Les formes progressives de l'esclerosi múltiple (EM) afecten més d'un milió de persones a tot el món. Les recents aprovacions d'ocrelizumab per a l'EM progressiva primària i siponimod per a l'EM secundària activa han obert la porta terapèutica, encara que els resultats dels primers assajos d'agents neuroprotectors han estat mixtos. La recent introducció del terme EM progressiva "secundària" en el lèxic terapèutic ha introduït una potencial confusió en la descripció de la malaltia i per tant en el maneig clínic. Objectiu: Aquest document revisa els progressos recents, destaca el coneixement continuat i proposa, en nom de l'Aliança Internacional d'EM Progressiva, una estratègia global de recerca per a l'EM progressiva. Mètodes: Es van realitzar cerques bibliogràfiques a PubMed entre 2015 i maig del 2021 usant els termes de cerca "esclerosi múltiple progressiva", "EM progressiva primària" i "EM secundària progressiva". Les estratègies proposades es van desenvolupar mitjançant una sèrie de reunions presencials i virtuals del Comitè Directiu Científic de l'Aliança Internacional d'EM Progressiva. Resultats: El manteniment i acceleració dels progressos requerirà un major enteniment dels mecanismes subjacents, la identificació de potencials objectius terapèutics, el descobriment i validació de biomarcadors, així com la realització d'assajos clínics amb un millor disseny. Els desenvolupaments encoratjadors en les intervencions simptomàtiques i rehabilitadores estan començant a abordar els reptes experimentats per persones amb EM progressiva. Conclusió: Hem de gestionar aquests reptes i aprofitar les oportunitats en el context d'una estratègia global de recerca, que millorarà la qualitat de vida de les persones amb EM progressiva.

Idioma original	Anglès
Pàgines (de-a)	16-28
Nombre de pàgines	13
Revista	Multiple Sclerosis Journal
Volum	28
Número	1
DOIs	https://doi.org/10.1177/13524585211059766
Estat de la publicació	Publicada - de gen. 2022

Accés al document

10.1177/13524585211059766

https://ddd.uab.cat/record/275819

Altres arxius i enllaços

Link to publication in Scopus

Com citar-ho

Thompson, A. J., Carroll, W., Ciccarelli, O., Comi, G., Cross, A., Donnelly, A., Feinstein, A., Fox, R. J., Helme, A., Hohlfeld, R., Hyde, R., Kanellis, P., Landsman, D., Lubetzki, C., Marrie, R. A., Morahan, J., Montalban, X., Musch, B., Rawlings, S., ... Coetzee, T. (2022). Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal. Multiple Sclerosis Journal, 28(1), 16-28. https://doi.org/10.1177/13524585211059766

@article{d1287e1438d747b2b9295f2365daca2d,

title = "Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal",

abstract = "Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term {\textquoteleft}active{\textquoteright} secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms “progressive multiple sclerosis”, “primary progressive multiple sclerosis”, “secondary progressive MS”. Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.",

keywords = "Multiple sclerosis, progression, progressive, progressive multiple sclerosis",

author = "Thompson, \{Alan J.\} and William Carroll and Olga Ciccarelli and Giancarlo Comi and Anne Cross and Alexis Donnelly and Anthony Feinstein and Fox, \{Robert J.\} and Anne Helme and Reinhard Hohlfeld and Robert Hyde and Pamela Kanellis and Douglas Landsman and Catherine Lubetzki and Marrie, \{Ruth Ann\} and Julia Morahan and Xavier Montalban and Bruno Musch and Sarah Rawlings and Marco Salvetti and Finn Sellebjerg and Caroline Sincock and Smith, \{Kathryn E.\} and Jon Strum and Paola Zaratin and Timothy Coetzee",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2022",

month = jan,

doi = "10.1177/13524585211059766",

language = "English",

volume = "28",

pages = "16--28",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "1",

}

Thompson, AJ, Carroll, W, Ciccarelli, O, Comi, G, Cross, A, Donnelly, A, Feinstein, A, Fox, RJ, Helme, A, Hohlfeld, R, Hyde, R, Kanellis, P, Landsman, D, Lubetzki, C, Marrie, RA, Morahan, J, Montalban, X, Musch, B, Rawlings, S, Salvetti, M, Sellebjerg, F, Sincock, C, Smith, KE, Strum, J, Zaratin, P & Coetzee, T 2022, 'Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal', Multiple Sclerosis Journal, vol. 28, núm. 1, pàg. 16-28. https://doi.org/10.1177/13524585211059766

TY - JOUR

T1 - Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

AU - Thompson, Alan J.

AU - Carroll, William

AU - Ciccarelli, Olga

AU - Comi, Giancarlo

AU - Cross, Anne

AU - Donnelly, Alexis

AU - Feinstein, Anthony

AU - Fox, Robert J.

AU - Helme, Anne

AU - Hohlfeld, Reinhard

AU - Hyde, Robert

AU - Kanellis, Pamela

AU - Landsman, Douglas

AU - Lubetzki, Catherine

AU - Marrie, Ruth Ann

AU - Morahan, Julia

AU - Montalban, Xavier

AU - Musch, Bruno

AU - Rawlings, Sarah

AU - Salvetti, Marco

AU - Sellebjerg, Finn

AU - Sincock, Caroline

AU - Smith, Kathryn E.

AU - Strum, Jon

AU - Zaratin, Paola

AU - Coetzee, Timothy

PY - 2022/1

Y1 - 2022/1

N2 - Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term ‘active’ secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms “progressive multiple sclerosis”, “primary progressive multiple sclerosis”, “secondary progressive MS”. Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.

AB - Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million individuals globally. Recent approvals of ocrelizumab for primary progressive MS and siponimod for active secondary progressive MS have opened the therapeutic door, though results from early trials of neuroprotective agents have been mixed. The recent introduction of the term ‘active’ secondary progressive MS into the therapeutic lexicon has introduced potential confusion to disease description and thereby clinical management. Objective: This paper reviews recent progress, highlights continued knowledge and proposes, on behalf of the International Progressive MS Alliance, a global research strategy for progressive MS. Methods: Literature searches of PubMed between 2015 and May, 2021 were conducted using the search terms “progressive multiple sclerosis”, “primary progressive multiple sclerosis”, “secondary progressive MS”. Proposed strategies were developed through a series of in-person and virtual meetings of the International Progressive MS Alliance Scientific Steering Committee. Results: Sustaining and accelerating progress will require greater understanding of underlying mechanisms, identification of potential therapeutic targets, biomarker discovery and validation, and conduct of clinical trials with improved trial design. Encouraging developments in symptomatic and rehabilitative interventions are starting to address ongoing challenges experienced by people with progressive MS. Conclusion: We need to manage these challenges and realise the opportunities in the context of a global research strategy, which will improve quality of life for people with progressive MS.

KW - Multiple sclerosis

KW - progression

KW - progressive

KW - progressive multiple sclerosis

UR - https://www.scopus.com/pages/publications/85121005286

U2 - 10.1177/13524585211059766

DO - 10.1177/13524585211059766

M3 - Review article

C2 - 34850641

AN - SCOPUS:85121005286

SN - 1352-4585

VL - 28

SP - 16

EP - 28

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 1

ER -

Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal

Resum

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho